In contrast, commercial PTX product and non-targeted variant, i.e., PTX@BSA NPs endowed 19.04 ± 4.12 μg/ml and 28.34 ± 5.28 μg/ml, respectively, suggesting CD44 targeted chemotherapy is an efficient strategy to treat melanoma with low-cost HA as a targeting moiety. This evidence concerns the gene CD44 and melanoma.